###### Strengths and limitations of this study

-   Hip fracture accelerated surgical treatment and care track is a large international trial designed to address whether early surgery can improve outcomes in patients with a hip fracture.

-   This substudy will provide robust estimates on the effects of early versus later surgery on the risk of acute kidney injury.

-   Patients and providers are not blinded to the intervention; however, objective measures are used to assess outcomes and outcome assessors are blinded to the intervention assignment.

Introduction {#s1}
============

Each year, millions of adults worldwide sustain a hip fracture and require surgical repair.[@R1] Complications are common, and the 90-day risk of mortality is 10%--20%. Shortening the time to surgery shows promise for reducing patient morbidity and mortality,[@R3] and this strategy is currently being tested in comparison with usual care in a multinational randomised controlled trial: the Hip fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) trial.[@R6] HIP ATTACK has two coprimary outcomes: the 90-day risk of (1) all-cause mortality and (2) major perioperative complications.

One lesser known complication of hip fracture is acute kidney injury (AKI). The development of AKI associates with a longer hospital stay, increased healthcare costs and a higher risk of death.[@R7] Approximately 15%--20% of patients who undergo surgery for a hip fracture will experience AKI, with 0.5%--1.8% receiving dialysis as a result.[@R10] A hip fracture exposes patients to trauma, pain, bleeding, hypotension and dehydration, which can lead to decreased renal perfusion and a heightened inflammatory state, all of which can contribute to the development of AKI.[@R13] A shorter time to surgery after a hip fracture can decrease the exposure time to such contributors and therefore may reduce the risk of AKI.

This protocol describes a planned kidney substudy of the HIP ATTACK trial to determine if a strategy of accelerated medical assessment and surgical repair, compared with usual care, reduces the risk of AKI in patients who suffer a hip fracture. To do this, we worked with the investigators of the main trial during its planning stages and arranged to provide substudy funding to trial centres to collect additional follow-up measures of serum creatinine. A subgroup analysis by baseline chronic kidney disease (CKD), the most prominent risk factor for AKI, will also be conducted.[@R15]

Methods and analysis {#s2}
====================

Overview of the main HIP ATTACK trial {#s2-1}
-------------------------------------

The HIP ATTACK trial is a multinational, parallel-group superiority randomised controlled trial of patients who present to the emergency department with a hip fracture requiring surgical repair. The main trial protocol is described elsewhere.[@R6] Briefly, patients who sustained a hip fracture were randomly allocated (1:1) to receive accelerated medical assessment and surgical repair (with the goal of having the surgery performed within 6 hours after the orthopaedic diagnosis) or usual care (where a repair typically occurs 24--48 hours after diagnosis). Enrolment occurred between March 2014 and May 2019, and 3001 patients from 70 centres in 18 countries were randomised. Follow-up assessments will continue until August 2019 for the primary analysis. All participating centres obtained ethics board approval to conduct the trial, and all patients provided informed consent to trial participation before enrolling.

Patient recruitment, eligibility and informed consent {#s2-2}
-----------------------------------------------------

Patients were recruited from the emergency department. Eligibility criteria for the main HIP ATTACK trial are fully detailed in the published protocol.[@R6] Eligible patients included those aged 45 years or older diagnosed with a hip fracture with a low-energy mechanism (eg, a fracture sustained from a fall not beyond standing height) requiring surgery. To align with the ability to deliver the trial intervention, the diagnosis had to be made during working hours. Exclusion criteria were as follows: (1) patients requiring emergent surgery or emergent interventions for another reason; (2) open hip fracture; (3) bilateral hip fractures; (4) periprosthetic fracture; (5) therapeutic anticoagulation for which there is no reversing agent available; (6) patients on therapeutic vitamin K antagonist with a history of heparin induced thrombocytopaenia (7) patients refusing participation and (8) patients previously enrolled in the trial.

All patients enrolled in HIP ATTACK after the centre of enrolment initiated kidney data collection will be included in the final substudy analysis with the exception of the following:

i.  Patients with prerandomisation end-stage kidney disease defined as prerandomisation estimated glomerular filtration rate (eGFR) \<15 mL/min per 1.73 m^2^, receipt of chronic dialysis or a kidney transplant. These patients will be excluded because the prevention of AKI is no longer relevant. We expect less than 2% of randomised patients to be excluded for this reason.

ii. Patients with no prerandomisation serum creatinine measurement since this measure is needed to identify AKI, which is defined by an acute increase in serum creatinine from the prerandomisation value. We expect approximately 24% of patients to be excluded for this reason.

Randomisation {#s2-3}
-------------

Randomisation was performed at the time of consent via an interactive web randomisation system maintained by the trial coordinating centre at the Population Health Research Institute, part of McMaster University in Hamilton, Ontario, Canada. This method ensures that the randomisation sequence is concealed from participating centres and patients. Patients were randomly allocated (1:1) to receive the intervention of accelerated medical clearance and surgery or usual care. The randomisation was performed using random permuted blocks of varying sizes that were unknown to research personnel and investigators. Stratification occurred by centre and planned surgery type (open reduction and internal fixation or arthroplasty). Due to the nature of the trial intervention, it was not possible to blind research personnel, healthcare providers or participants to the randomised allocation; however, data collectors and outcome adjudicators were unaware of the patient's randomised allocation.

Trial intervention {#s2-4}
------------------

The trial intervention was an accelerated medical assessment and surgical repair, with the goal of performing the surgery within 6 hours of the orthopaedic diagnosis. Patients underwent medical clearance by an on-call medical specialist (ie, an internist, geriatrician, cardiologist or anaesthesiologist) who was able to quickly come to the emergency department and perform the assessment. Specialists used their own clinical judgement and weighed the potential risks and benefits of rapidly clearing patients for surgery.[@R3] The patient's orthopaedic surgeon and anaesthesiologist also had to agree that the patient was an appropriate surgical candidate. Following medical clearance, research personnel informed all relevant parties (ie, the surgical booking clerk, orthopaedic surgeon and anaesthesiologist), and patients were moved to the next available orthopaedic trauma room or elective operating room such that their surgeries were prioritised over scheduled elective cases. All other perioperative care was at the discretion of the attending team. Further logistical details are provided in the pilot report and the main trial protocol.[@R3]

Patients randomly allocated to the usual-care group were placed on the wait list for surgery according to local standard practices.

Substudy data collection {#s2-5}
------------------------

The prerandomisation (baseline) serum creatinine concentration was obtained from a review of medical records in the 30-day period before hip fracture surgery (as part of routine care, most patients have their serum creatinine tested at the time of emergency room presentation). The most recent test result before randomisation will serve as the baseline value. To accurately capture postrandomisation AKI, all study centres were given substudy funds to measure and record daily serum creatinine values for 7 days after randomisation or until hospital discharge, whichever came first. The highest serum creatinine value recorded between randomisation and hospital discharge was also recorded. Research personnel followed all patients daily during their time in hospital to improve adherence to the scheduled creatinine measurements. Receipt of new dialysis for kidney failure was recorded at hospital discharge and at 30 days after randomisation.

Substudy outcomes {#s2-6}
-----------------

The primary outcome of the kidney substudy is AKI, defined as an increase in the serum creatinine concentration from the prerandomisation value of ≥26.5 μmol/L (≥0.3 mg/dL) within 48 hours after randomisation or an increase of ≥50% within 7 days after randomisation.[@R16]

Secondary definitions of AKI {#s2-7}
----------------------------

Six secondary assessments of AKI will be examined to assess whether the primary results are robust:

1.  A composite of AKI (primary outcome definition) or death within 48 hours after randomisation which will serve to account for the potential impact of early deaths on outcome ascertainment.

2.  Stage 2 AKI (or higher), defined as a postrandomisation increase in serum creatinine of 100% or more from the prerandomisation value within 7 days after randomisation or an increase to an absolute value of 353.6 μmol/L or more (≥4.0 mg/dL) within 7 days after randomisation (when the primary outcome definition of AKI is met) or receipt of dialysis within 30 days after randomisation.

3.  Stage 3 AKI, defined as a postrandomisation increase in serum creatinine of 200% or more from the prerandomisation value within 7 days after randomisation or an increase to an absolute value of 353.6 μmol/L or more (≥4.0 mg/dL) within 7 days after randomisation or receipt of dialysis within 30 days after randomisation.

4.  Receipt of dialysis within 30 days after randomisation.

5.  Percentage change in serum creatinine in the first 7 days after randomisation, defined as follows: ((peak postrandomisation serum creatinine---prerandomisation serum creatinine)/prerandomisation serum creatinine) times 100.

6.  Absolute change in serum creatinine in the first 7 days after randomisation, defined as follows: peak postrandomisation serum creatinine---prerandomisation serum creatinine.

Statistical considerations {#s2-8}
--------------------------

### Sample size {#s2-8-1}

The main HIP ATTACK trial enrolled 3001 patients, and more than 90% of these patients were enrolled after the initiation of the renal substudy protocol. We expect that approximately 74% of these patients will be eligible for inclusion in the kidney substudy. A sample of 1998 patients will provide over 80% power to detect a relative risk (RR) reduction of 30% for the primary outcome of AKI (two-sided α=0.05), comparing the accelerated approach to usual care, assuming the incidence of AKI is 14% in the usual-care group, after accounting for 4% missing AKI status. Approximately 10%--12% of patients develop postoperative AKI.[@R17] In hip fracture patients, AKI incidence is even higher, around 15%--20%.[@R10] With these data in mind, we used a conservative 14% AKI incidence for the usual care group to perform the sample size calculation to ensure we would have adequate statistical power to detect a 30% RR reduction in the primary outcome, if it in truth exists.

### Statistical analysis plan {#s2-8-2}

In the primary analysis (intention to treat), a modified Poisson regression model which accounts for the treating centre will be used to estimate the RR and 95% CI for AKI comparing the intervention group to the usual-care group.[@R19] For patients enrolled in the substudy without a postrandomisation serum creatinine value (expected for ≤4% of patients), for the primary analysis model-based multiple imputation methods, using all available data, will be used to impute AKI status.[@R18] Parameters will be estimated using standard methods while allowing for extra imputation variability.[@R23] A two-tailed p value \<0.05 will be considered statistically significant. In our experience, with previous AKI perioperative substudies of large clinical trials, the unadjusted and adjusted results were virtually identical,[@R18] and therefore we have not prespecified any adjusted analyses for this substudy.

### Prespecified supporting analyses {#s2-8-3}

Several supporting analyses will be conducted to examine whether there is concordance with the primary analysis. These will include a complete case analysis, an examination of six secondary assessments of AKI and a subgroup analysis of patients with prerandomisation CKD.

### Complete case analysis {#s2-8-4}

We will perform a complete case analysis restricted to patients with at least one postrandomisation serum creatinine measurement which is expected to involve greater than 96% of patients in the primary analysis.

### Alternative secondary assessments of AKI {#s2-8-5}

We will examine six secondary assessments of AKI (four categorical and two continuous, as described above). RR estimates will be estimated using modified Poisson regression models and continuous outcomes using linear regression models. We will visually inspect the point estimates and 95% CIs and assess concordance with the primary analysis. Given our sample size, analyses of severe AKI will have limited statistical power for small effects.

### Subgroup analysis {#s2-8-6}

The risk of AKI will be examined in patients with and without CKD as defined by a prerandomisation eGFR \<60 mL/min per 1.73 m² as assessed with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.[@R26] We hypothesise a greater absolute risk reduction of AKI with accelerated versus routine surgery in patients with CKD compared with patients without CKD. The p value for the interaction (CKD × intervention group) will be assessed in a regression model for binary outcome data.

### Patient and public involvement statement {#s2-8-7}

There was no direct patient involvement in designing this substudy. Previously, we reported the patient involvement in the main trial in the HIP ATTACK protocol paper.[@R6]

Ethics and dissemination {#s3}
========================

We obtained ethics approval in all centres, and all patients provided informed consent before randomisation (see [online supplementary material](#SP1){ref-type="supplementary-material"}). The dissemination policy will include publication in a peer-reviewed journal and presentations at relevant conferences. The clinical results of this substudy will be incorporated in the HIP ATTACK dissemination plan, including reporting the results in the HIP ATTACK open website (<http://www.hipattacktrial.com>), the HIP ATTACK Twitter account (\@HIPATTACKTrial), LinkedIn Profile, the Facebook page and the Reducing Global Perioperative Risk Multimedia Resource Center. This is an online media linked to Elsevier's entire international readership, through which we will disseminate the full-text articles, links to abstracts and data summaries. We expect the substudy results to be reported by 2021.
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Discussion {#s4}
==========

HIP ATTACK is a multinational randomised controlled trial that will determine if a strategy of accelerated medical clearance and surgery compared with usual care improves outcomes for patients with a hip fracture. The present protocol describes a prespecified kidney substudy of HIP ATTACK that will examine the effect of this strategy on the risk of AKI.

AKI is a known consequence of surgery. By adding additional serum creatinine measurements to HIP ATTACK, we will efficiently and reliably determine whether a strategy of accelerated medical clearance and hip surgery reduces the risk of AKI compared with a usual care. The strengths of this substudy include its randomised trial methodology with concealed allocation, patient recruitment from 70 centres across 18 countries and standardised collection of postrandomisation serum creatinine. The primary outcome and statistical analysis plan are prespecified, and multiple sensitivity analyses are planned to examine the robustness of the primary results.

This substudy has some limitations. First, given the trial's design, we expect that approximately 76% of patients' baseline (prerandomisation) serum creatinine will be obtained at the time of emergency room presentation for hip fracture, and depending on the circumstances of the fracture, some of these patients' serum creatinine concentrations may be unstable or elevated. Instability in baseline serum creatinine may make it difficult to detect an acute rise in postrandomisation serum creatinine, which is needed for the identification of AKI. To examine this issue, we will compare the mean baseline serum creatinine concentration in a subset of patients with serum creatinine measurements before and after hip fracture. Second, similar to other perioperative studies,[@R18] urine output data are not collected in HIP ATTACK given the difficulties with accurate measurement in the setting of international data collection. Third, the most clinically relevant renal outcome would be new kidney failure treated with dialysis. Although we are measuring this outcome, we anticipate that it will occur infrequently (\<1%), and therefore the analysis of this outcome will have limited statistical power. Finally, we have over 80% power to detect a 30% or more relative risk reduction in our primary outcome of AKI. As previously described, we will examine changes in the perioperative concentration of serum creatinine as a continuous measure, which might be of particular relevance if the primary outcome is not significant and there are concerns that this is due to a lack of statistical power.

In summary, this prespecified substudy of HIP ATTACK, a large multinational trial, will address the question whether a strategy of accelerated medical clearance and surgery for hip fracture improves renal outcomes.
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